epigallocatechin gallate has been researched along with Cytokine Release Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertoldi, M; Campagnari, R; Crupi, R; Cuzzocrea, S; Di Paola, R; Menegazzi, M | 1 |
1 review(s) available for epigallocatechin gallate and Cytokine Release Syndrome
| Article | Year |
|---|---|
Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
Topics: Anti-Inflammatory Agents; Antioxidants; Autoimmune Diseases; Betacoronavirus; Catechin; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; NF-kappa B; Pandemics; Plant Extracts; Pneumonia, Viral; Pulmonary Fibrosis; SARS-CoV-2; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor | 2020 |